BR9712197A - Aqueous liquid pharmaceutical formulation and processes for preparing it, and for inhibiting bone resorption. - Google Patents

Aqueous liquid pharmaceutical formulation and processes for preparing it, and for inhibiting bone resorption.

Info

Publication number
BR9712197A
BR9712197A BR9712197-5A BR9712197A BR9712197A BR 9712197 A BR9712197 A BR 9712197A BR 9712197 A BR9712197 A BR 9712197A BR 9712197 A BR9712197 A BR 9712197A
Authority
BR
Brazil
Prior art keywords
processes
pharmaceutical formulation
preparing
liquid pharmaceutical
aqueous liquid
Prior art date
Application number
BR9712197-5A
Other languages
Portuguese (pt)
Inventor
Maneesh J Nerurkaar
William H Hunke
Drazen Ostovic
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9700541.7A external-priority patent/GB9700541D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BR9712197A publication Critical patent/BR9712197A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçãO FARMACêUTICA LìQUIDA AQUOSA E PROCESSOS DE PREPARAçãO DA MESMA, E, DE INIBIçãO DE REABSORçãO DE OSSO". Uma formulação líquida de ácido alendrónico ou de um sal farmaceuticamente aceitável tem suficiente tampão de modo que o pH da formulação seja 4-7,5, e 15 ml da formulação sejam capazes de aumentar o pH de 50 ml de HC1 0,1 N de um até pelo menos 3 e de preferência 4."LIQUID LIQUID PHARMACEUTICAL FORMULATION AND PREPARATION PROCESSES OF THE SAME, AND, INHIBITION OF BONE REABSORPTION". A liquid formulation of alendronic acid or a pharmaceutically acceptable salt has sufficient buffer so that the pH of the formulation is 4-7.5, and 15 ml of the formulation is able to raise the pH to 50 ml of 0.1 N HCl. one to at least 3 and preferably 4.

BR9712197-5A 1996-10-04 1997-10-02 Aqueous liquid pharmaceutical formulation and processes for preparing it, and for inhibiting bone resorption. BR9712197A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2676596P 1996-10-04 1996-10-04
GBGB9700541.7A GB9700541D0 (en) 1997-01-13 1997-01-13 Liquid alendronate formulation
US3600297P 1997-01-22 1997-01-22
PCT/US1997/015740 WO1998014196A1 (en) 1996-10-04 1997-10-02 Liquid alendronate formulations

Publications (1)

Publication Number Publication Date
BR9712197A true BR9712197A (en) 1999-08-31

Family

ID=27268667

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712197-5A BR9712197A (en) 1996-10-04 1997-10-02 Aqueous liquid pharmaceutical formulation and processes for preparing it, and for inhibiting bone resorption.

Country Status (20)

Country Link
EP (1) EP1007054A4 (en)
JP (1) JP2001501222A (en)
CN (1) CN1238691A (en)
AU (1) AU723357B2 (en)
BG (1) BG103306A (en)
BR (1) BR9712197A (en)
CA (1) CA2267370A1 (en)
CZ (1) CZ116999A3 (en)
EA (1) EA001213B1 (en)
EE (1) EE03669B1 (en)
HU (1) HUP0000125A3 (en)
IL (1) IL129127A0 (en)
IS (1) IS5012A (en)
NO (1) NO991569L (en)
NZ (1) NZ334836A (en)
PL (1) PL332496A1 (en)
SK (1) SK42999A3 (en)
TR (1) TR199900730T2 (en)
WO (1) WO1998014196A1 (en)
YU (1) YU17499A (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560490B2 (en) * 2001-01-23 2009-07-14 Gador S.A. Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
US20080286359A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080287400A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
JP2009508834A (en) * 2005-09-16 2009-03-05 セラマイン リミテッド Bisphosphonate formulation
JP2010043119A (en) * 2009-10-16 2010-02-25 Gador Sa Composition for preventing and/or treating bone metabolic disease, method of preparing the same and use thereof
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206209A (en) * 1978-11-02 1980-06-03 Kracauer Paul Sublingual aspirin tablet
IT1201087B (en) * 1982-04-15 1989-01-27 Gentili Ist Spa PHARMACOLOGICALLY ACTIVE BIPPHOSPHONES, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FR2703590B1 (en) * 1993-04-05 1995-06-30 Sanofi Elf USE OF BISPHOSPHONIC ACID DERIVATIVES FOR THE PREPARATION OF MEDICINES FOR PROMOTING BONE REPAIR.
US5510517A (en) * 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy

Also Published As

Publication number Publication date
TR199900730T2 (en) 1999-07-21
YU17499A (en) 1999-11-22
SK42999A3 (en) 2000-01-18
EA001213B1 (en) 2000-12-25
EA199900352A1 (en) 1999-08-26
EE03669B1 (en) 2002-04-15
CZ116999A3 (en) 1999-09-15
IL129127A0 (en) 2000-02-17
IS5012A (en) 1999-03-26
BG103306A (en) 2000-01-31
AU723357B2 (en) 2000-08-24
EP1007054A4 (en) 2000-07-19
WO1998014196A1 (en) 1998-04-09
CA2267370A1 (en) 1998-04-09
NO991569L (en) 1999-06-04
PL332496A1 (en) 1999-09-13
EE9900113A (en) 1999-10-15
AU4644897A (en) 1998-04-24
EP1007054A1 (en) 2000-06-14
NZ334836A (en) 2000-11-24
HUP0000125A2 (en) 2000-06-28
NO991569D0 (en) 1999-03-30
CN1238691A (en) 1999-12-15
JP2001501222A (en) 2001-01-30
HUP0000125A3 (en) 2001-04-28

Similar Documents

Publication Publication Date Title
ES2244831T5 (en) Use of panthenol and / or pantothenic acid and hyaluronic acid and / or hyaluronate for the production of a pharmaceutical composition for ophthalmological application
KR970706830A (en) COMPOSITION OF CISPLATIN IN COMBINATION WITH 2, 2'-DITHIO-BIS (ETHANESULFONATE) (DIMESNA)
UA40663C2 (en) controlled release, solid pharmaceutical composition adapted for oral administration
BR0215240A (en) Calcium derivatives and their use in treating diseases
BR0214757A (en) Pharmaceutical Formulations of Platinum Derivatives
NZ234143A (en) Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
MY130157A (en) Method of use for inhibiting bone loss and lowering serum cholesterol
NO20022264L (en) Pharmaceutical composition containing tolterodine and its use
CA2671383A1 (en) Dried composition
WO2002072073A3 (en) Pharmaceutical formulation comprising atorvastatin calcium
RU94041223A (en) Agent for motoneuron disease treatment
MY128654A (en) Liquid pharmaceutical composition containing an erythropoietin derivative
BR9712197A (en) Aqueous liquid pharmaceutical formulation and processes for preparing it, and for inhibiting bone resorption.
BR0008323A (en) Gabapentin derivative for the prevention and treatment of visceral pain
MX9504034A (en) Medical administering forms containing tioctic acid, or tioctic acid solid salts having improved release and bioavailability.
FI110667B (en) Pharmaceutical prepn. of di:chloro-methylene bis-phosphonic acid with enteric coating - used for treating diseases relating to calcium metabolism and the skeletal system
BR0212787A (en) Pharmaceutically acceptable compound or salt thereof, methods of treating or preventing disease and preparing a compound, use of a compound or salt, and pharmaceutical composition
TR200101163T2 (en) Bile water substituted phenyl-alkenoylguanidines, production methods, uses
EA199900830A1 (en) THERAPEUTIC MINERALOVITAMIN ASSOCIATION IN THE FORM OF UNITARY LIQUID PREPARATION FOR DRINKING
SI0875248T1 (en) Use of hyaluronic acid for the preparation of an aqueous solution useful as intra-articular lavage liquid
FR2684381B1 (en) COMPOUNDS HAVING A PHOSPHORIC AMIDE LINK OR AN ENOL PHOSPHATE LINK FOR THEIR APPLICATION AS A THERAPEUTICALLY ACTIVE SUBSTANCE.
KR910005886A (en) Stabilized Leukocyte Interferon
PT1218401E (en) 4-BENZYLAMINOQUINOLINS CONTAINED WITH BILIARY ACID AND ITS HETEROCYCLICS METHODS OF THEIR PRODUCTION MEDICINES CONTAINING THESE COMPOUNDS AND ITS APPLICATION
PT711163E (en) USE OF BENZIDAMINE IN THE TREATMENT OF TNF-INDUCED PATHOLOGICAL STATES
AU9095291A (en) Sterilising composition

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.